The UK and US have reached a major trade agreement that will maintain no tariffs on British drug shipments entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise spending on medicines through the public health system. This move guarantees that duties on these key goods will remain at zero for a timeframe of three years.
This development comes after previous threats to dramatically increase tariffs on patented drug imports, with potential rates mentioned reaching 100%.
"This arrangement between the Britain bolsters the global environment for new treatments and brings much-needed balance to transatlantic medicine commerce," a statement said.
Commercial Impact
Medicines are one of the UK's biggest exports to the United States, which is easily the largest buyer for large British pharmaceutical firms.
Trade data reveal that in the one-year period to the end of the third quarter, the UK exported drugs valued at over eleven billion pounds to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This guarantee secures employment, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for biotech and pharma," a government official remarked.
Detailed UK Commitments
The pact involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall health service expenditure on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to control costs will be limited at fifteen percent. Last year, repayments were more than 20%.
Broader Context
This agreement comes amid a ongoing tension between the drug companies and the ministers over spending levels and approval rates.
The disagreement were exacerbated by assertions that US customers were paying significantly more for the identical medicines than people in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
A senior figure acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its overall budget over the previous ten-year period.
